Browsing by Subject
Ara mostrant els elements 1-20 d 32
-
A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancer
(Future Medicine, 2023-08) -
Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial
(American Medical Association, 2023-11) -
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial
(American Society of Clinical Oncology, 2023-10-20) -
Cetuximab every 2 weeks versus standard weekly dosing administration schedule
(Future Medicine, 2024-03) -
Dostarlimab: From preclinical investigation to drug approval and future directions
(Taylor & Francis, 2023) -
Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment
(Wiley, 2022-06) -
Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin
(Nature Portfolio, 2023-05-23) -
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
(Nature Portfolio, 2023-06-07)